GLP-1 therapies have transformed obesity management and created one of the fastest-growing pharmaceutical markets in history. Yet significant challenges remain, including gastrointestinal side effects, treatment discontinuation, muscle mass loss and long-term adherence concerns. As biopharma companies race to address these limitations, a new generation of therapies is emerging. Oral treatments, ultra-long-acting formulations, muscle-preserving approaches and entirely new mechanisms of action are redefining what obesity treatment could look like over the next decade.

In this latest edition of the Companies to Watch series, analysts examine the trends, technologies and innovators shaping the future of obesity treatment.